Full Breakdown
Experimental Ebola Therapies Used for U.S. Patient Amid DRC Bundibugyo Outbreak
5/23/2026, 6:53:59 AM
U.S. Patient Treated with Experimental Drugs
U.S. missionary Dr. Peter Stafford tested positive for the Bundibugyo strain of Ebola and is receiving experimental therapies at a German hospital. U.S. health officials confirmed treatment but did not disclose the specific agents.
Outbreak Context
The World Health Organization declared the DRC outbreak a public-health emergency on 17 May. The CDC reported 336 suspected cases and 88 deaths; other sources cite roughly 750 infections and 177 fatalities. No vaccine or drug is approved for the Bundibugyo strain.
Preclinical Data and Key Players
Key researchers include virologist Thomas Geisbert (UTMB), Gilead Sciences (obeldesivir), and Mapp Biopharmaceutical (MBP134). In monkeys, obeldesivir prevented Ebola Sudan infection and protected 80-100 % against Marburg and Ebola Zaire, but has not been tested against Bundibugyo. MBP134 rescued five of six symptomatic monkeys infected with Bundibugyo, achieving full recovery in five. An experimental vaccine from Geisbert’s team protected monkeys and he estimates the approved Ervebo vaccine would be about 50 % effective against Bundibugyo.
Official Statements and Agency Actions
The WHO called obeldesivir a promising candidate and said vaccine development could take six to nine months. Gilead’s spokesperson Ashleigh Koss said the company is in contact with health authorities. Mapp confirmed collaboration with the WHO and BARDA and has enough MBP134 for a trial, though its president declined to confirm use for Americans in Europe. The CDC declined comment on the patient’s treatment. Africa CDC is reviewing an Ervebo trial. A WHO-sponsored trial awaits DRC and Ugandan approval.
Criticism and Uncertainties
Experts note the absence of human efficacy data for obeldesivir against Bundibugyo and uncertainty about its performance in symptomatic patients. MBP134 has only compassionate-use experience in a Sudan Ebola outbreak, with no definitive outcome data. Vaccine effectiveness against Bundibugyo remains speculative, with estimates ranging from 0 % to 50 %.
Conflicting Reports and Gaps
Case counts differ between sources (750 infections/177 deaths versus 336 suspected cases/88 deaths). Vaccine efficacy estimates vary, and no clinical data exist for the experimental antivirals in Bundibugyo patients. The timeline for a definitive vaccine remains unclear.
Verbatim Quotes
- “I think that that's something that potentially has some utility here,” — Thomas Geisbert, Virologist, UTMB
- “This is mimicking somebody that walks into a clinic,” — Thomas Geisbert, Virologist, UTMB
- “I think we’re in a really strong position to quickly launch trials,” — Amanda Rojek, Clinical Researcher, University of Oxford
- “It’s a true therapeutic — we’ve used it against Bundibugyo and it works fantastically, and you can wait until they’re very sick,” — Thomas Geisbert, Virologist, UTMB
What’s Next
The WHO-sponsored trial of remdesivir and MBP134 will start once DRC and Ugandan regulators approve it; BARDA is preparing MBP134 supplies and agencies are reviewing an Ervebo trial.
